<p>根據 MarketBeat Ratings 的報告，目前有八家經紀公司對 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) 的股票給出了 “買入” 的一致推薦意見。七位研究分析師對該股票給出了買入評級，一位對該公司給出了強烈買入評級。過去一年對該股票進行評級的經紀公司的平均一年目標股價為 65.86 美元。</p>
<p>獲取 <strong>Corbus Pharmaceuticals</strong> 的警報：</p>
<ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
<p>近期，幾位股票研究分析師對該股票發表了看法。Oppenheimer 將 Corbus Pharmaceuticals 的股票價格目標從 80.00 美元上調至 88.00 美元，並在 8 月 7 日星期三的研究報告中給予該股票 “表現優異” 的評級。B. Riley 將 Corbus Pharmaceuticals 的股票價格目標從 85.00 美元下調至 40.00 美元，並在 9 月 20 日星期五的研究報告中給予該股票 “買入” 評級。Wedbush 將 Corbus Pharmaceuticals 的股票價格目標從 85.00 美元下調至 51.00 美元，並在 9 月 20 日星期五的研究報告中為該公司設定了 “表現優異” 的評級。Lifesci Capital 在 8 月 21 日星期三將 Corbus Pharmaceuticals 的評級提升至 “強烈買入”。最後，HC Wainwright 在 9 月 23 日星期一重申了對 Corbus Pharmaceuticals 的 “買入” 評級，並設定了 80.00 美元的目標股價。</p>
<p><strong>查看我們對 CRBP 的最新股票分析</strong></p>
<h2>Corbus Pharmaceuticals 股票下跌 3.5%</h2>
<ul>
<li>Corbus Pharmaceuticals 納斯達克：CRBP 發出大膽買入信號</li>
</ul>
<p>週五，納斯達克:CRBP 的股價開盤價為 19.21 美元。Corbus Pharmaceuticals 的 12 個月最低價為 3.03 美元，最高價為 61.90 美元。該公司的 50 天移動平均股價為 47.56 美元，200 天移動平均股價為 45.44 美元。該公司的市值為 2.053 億美元，市盈率為-2.76，β係數為 2.56。</p>
<p>Corbus Pharmaceuticals (NASDAQ:CRBP) 在 8 月 6 日星期二發佈了季度財報。這家生物製藥公司在該季度報告中每股虧損 0.90 美元，超過了分析師預期的每股虧損 1.19 美元，超額盈利 0.29 美元。研究分析師平均預計，Corbus Pharmaceuticals 今年將實現每股-3.77 美元的盈利。</p>
<h2>內部人員的買賣行為</h2>
<p>另外，主要股東 Cormorant Asset Management, Lp 於 9 月 20 日星期五以 20.01 美元的平均價格每股購買了該公司 35 萬股股票，交易總額為 700.35 萬美元。交易完成後，該內部人員現持有該公司 237.5 萬股股票，價值 4752.375 萬美元。這筆交易導致其對該股票的持股比例增加了 0.00%。該購買行為已在提交給美國證券交易委員會的法律文件中披露，可在此鏈接處查看。目前公司股份的 4.00% 歸公司內部人員所有。</p>
<h2>對 Corbus Pharmaceuticals 的對沖基金看法</h2>
<p>一些對沖基金最近調整了他們對 CRBP 的持股。SG Americas Securities LLC 在第三季度收購了 Corbus Pharmaceuticals 的新股份，價值 15.1 萬美元。Rhumbline Advisers 在第二季度收購了 Corbus Pharmaceuticals 的新股份，價值約 63.8 萬美元。Acadian Asset Management LLC 在第二季度購入了 Corbus Pharmaceuticals 的新股份，價值約 71.6 萬美元。ClariVest Asset Management LLC 在第二季度收購了 Corbus Pharmaceuticals 的新股份，價值約 72.5 萬美元。最後，Victory Capital Management Inc.在第二季度購入了 Corbus Pharmaceuticals 的新股份，價值約 86.2 萬美元。機構投資者和對沖基金擁有該公司 64.64% 的股份。</p>
<h2>Corbus Pharmaceuticals 公司簡介</h2>
<p>Corbus Pharmaceuticals Holdings, Inc 是一家生物製藥公司，致力於開發產品來治療嚴重疾病。該公司正在開發 CRB-701，一種抗體藥物結合物（ADC），用於靶向癌細胞上的 Nectin-4 表達，釋放單甲基花青素 E（MMAE）的細胞毒荷載，目前處於 I 期臨牀試驗階段；CRB-601，一種抗整合素單克隆抗體，用於阻斷癌細胞上表達的 TGFß的激活，用於治療實體腫瘤；CRB-913，一種外周限制性的大麻素 1（CB1）受體反向激動劑，用於治療肥胖。</p>
<h2>精選故事</h2>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA"/></p>
<p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ “美國即將迎來非常黑暗的一天”（來自 InvestorPlace）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njgy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njgy"/></p>
<h2>您現在是否應該投資 1000 美元購買 Corbus Pharmaceuticals 股票？</h2>
<p>在考慮投資 Corbus Pharmaceuticals 之前，您可能需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高且表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Corbus Pharmaceuticals 並不在這份名單上。</p>
<p>儘管 Corbus 製藥目前在分析師中擁有&#34;買入&#34;評級，但頂級分析師認為以下這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Corbus制藥控股

<p>Corbus 製藥控股公司（NASDAQ:CRBP）已經獲得了八家經紀公司的一致 “買入” 推薦。七位分析師給予了買入評級，而一位則給出了強烈買入評級。平均 1 年價格目標為 0.86 美元。最近的價格調整包括 Oppenheimer 將其目標價上調至 0.00 美元，而 B. Riley 將其下調至 0.00 美元。該股票今年以來上漲了 342%，當前價格為 0.21 美元。主要股東 Cormorant Asset Management 最近購買了 35 萬股，將其持股量增加至 237.5 萬股。機構投資者擁有公司 64.64% 的股份</p>

<p>Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of &#34;Buy&#34; from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $65.86.</p>
<div class="lb-trans"><p>根據 MarketBeat Ratings 的報告，目前有八家經紀公司對 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) 的股票給出了 “買入” 的一致推薦意見。七位研究分析師對該股票給出了買入評級，一位對該公司給出了強烈買入評級。過去一年對該股票進行評級的經紀公司的平均一年目標股價為 65.86 美元。</p>
</div><p>Get <strong>Corbus Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Corbus Pharmaceuticals stock: An explosive 342% YTD surge</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Corbus Pharmaceuticals</strong> 的警報：</p>
<ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
</div><p>Several equities research analysts recently weighed in on the stock. Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $80.00 to $88.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, August 7th. B. Riley decreased their price objective on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, September 20th. Wedbush lowered their price objective on shares of Corbus Pharmaceuticals from $85.00 to $51.00 and set an &#34;outperform&#34; rating for the company in a research report on Friday, September 20th. Lifesci Capital raised Corbus Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Wednesday, August 21st. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $80.00 price target on shares of Corbus Pharmaceuticals in a report on Monday, September 23rd.</p>
<div class="lb-trans"><p>近期，幾位股票研究分析師對該股票發表了看法。Oppenheimer 將 Corbus Pharmaceuticals 的股票價格目標從 80.00 美元上調至 88.00 美元，並在 8 月 7 日星期三的研究報告中給予該股票 “表現優異” 的評級。B. Riley 將 Corbus Pharmaceuticals 的股票價格目標從 85.00 美元下調至 40.00 美元，並在 9 月 20 日星期五的研究報告中給予該股票 “買入” 評級。Wedbush 將 Corbus Pharmaceuticals 的股票價格目標從 85.00 美元下調至 51.00 美元，並在 9 月 20 日星期五的研究報告中為該公司設定了 “表現優異” 的評級。Lifesci Capital 在 8 月 21 日星期三將 Corbus Pharmaceuticals 的評級提升至 “強烈買入”。最後，HC Wainwright 在 9 月 23 日星期一重申了對 Corbus Pharmaceuticals 的 “買入” 評級，並設定了 80.00 美元的目標股價。</p>
</div><p><strong>View Our Latest Stock Analysis on CRBP</strong></p>
<div class="lb-trans"><p><strong>查看我們對 CRBP 的最新股票分析</strong></p>
</div><h2>Corbus Pharmaceuticals Stock Down 3.5 %</h2>
<ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal</li>
</ul>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 股票下跌 3.5%</h2>
<ul>
<li>Corbus Pharmaceuticals 納斯達克：CRBP 發出大膽買入信號</li>
</ul>
</div><p>Shares of NASDAQ:CRBP opened at $19.21 on Friday. Corbus Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $61.90. The company's 50 day moving average price is $47.56 and its two-hundred day moving average price is $45.44. The firm has a market cap of $205.30 million, a PE ratio of -2.76 and a beta of 2.56.</p>
<div class="lb-trans"><p>週五，納斯達克:CRBP 的股價開盤價為 19.21 美元。Corbus Pharmaceuticals 的 12 個月最低價為 3.03 美元，最高價為 61.90 美元。該公司的 50 天移動平均股價為 47.56 美元，200 天移動平均股價為 45.44 美元。該公司的市值為 2.053 億美元，市盈率為-2.76，β係數為 2.56。</p>
</div><p>Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.29. On average, research analysts expect that Corbus Pharmaceuticals will post -3.77 EPS for the current year.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals (NASDAQ:CRBP) 在 8 月 6 日星期二發佈了季度財報。這家生物製藥公司在該季度報告中每股虧損 0.90 美元，超過了分析師預期的每股虧損 1.19 美元，超額盈利 0.29 美元。研究分析師平均預計，Corbus Pharmaceuticals 今年將實現每股-3.77 美元的盈利。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員的買賣行為</h2>
</div><p>In other news, major shareholder Cormorant Asset Management, Lp bought 350,000 shares of the company's stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $20.01 per share, for a total transaction of $7,003,500.00. Following the completion of the transaction, the insider now owns 2,375,000 shares of the company's stock, valued at $47,523,750. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 4.00% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>另外，主要股東 Cormorant Asset Management, Lp 於 9 月 20 日星期五以 20.01 美元的平均價格每股購買了該公司 35 萬股股票，交易總額為 700.35 萬美元。交易完成後，該內部人員現持有該公司 237.5 萬股股票，價值 4752.375 萬美元。這筆交易導致其對該股票的持股比例增加了 0.00%。該購買行為已在提交給美國證券交易委員會的法律文件中披露，可在此鏈接處查看。目前公司股份的 4.00% 歸公司內部人員所有。</p>
</div><h2>Hedge Funds Weigh In On Corbus Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Corbus Pharmaceuticals 的對沖基金看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of CRBP. SG Americas Securities LLC acquired a new stake in Corbus Pharmaceuticals in the third quarter valued at $151,000. Rhumbline Advisers acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at about $638,000. Acadian Asset Management LLC bought a new position in shares of Corbus Pharmaceuticals during the second quarter worth about $716,000. ClariVest Asset Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the second quarter worth approximately $725,000. Finally, Victory Capital Management Inc. bought a new stake in Corbus Pharmaceuticals in the second quarter valued at approximately $862,000. Institutional investors and hedge funds own 64.64% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近調整了他們對 CRBP 的持股。SG Americas Securities LLC 在第三季度收購了 Corbus Pharmaceuticals 的新股份，價值 15.1 萬美元。Rhumbline Advisers 在第二季度收購了 Corbus Pharmaceuticals 的新股份，價值約 63.8 萬美元。Acadian Asset Management LLC 在第二季度購入了 Corbus Pharmaceuticals 的新股份，價值約 71.6 萬美元。ClariVest Asset Management LLC 在第二季度收購了 Corbus Pharmaceuticals 的新股份，價值約 72.5 萬美元。最後，Victory Capital Management Inc.在第二季度購入了 Corbus Pharmaceuticals 的新股份，價值約 86.2 萬美元。機構投資者和對沖基金擁有該公司 64.64% 的股份。</p>
</div><h2>Corbus Pharmaceuticals Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 公司簡介</h2>
</div><p>Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals Holdings, Inc 是一家生物製藥公司，致力於開發產品來治療嚴重疾病。該公司正在開發 CRB-701，一種抗體藥物結合物（ADC），用於靶向癌細胞上的 Nectin-4 表達，釋放單甲基花青素 E（MMAE）的細胞毒荷載，目前處於 I 期臨牀試驗階段；CRB-601，一種抗整合素單克隆抗體，用於阻斷癌細胞上表達的 TGFß的激活，用於治療實體腫瘤；CRB-913，一種外周限制性的大麻素 1（CB1）受體反向激動劑，用於治療肥胖。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Corbus Pharmaceuticals</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>The Outlook for Interest Rate Cuts Got Blown Out of the Water</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore</li>
<li>What is Forex and How Does it Work?</li>
<li>3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRBP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ “A very dark day is coming to America” (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ “美國即將迎來非常黑暗的一天”（來自 InvestorPlace）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njgy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9682&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Corbus Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1000 美元購買 Corbus Pharmaceuticals 股票？</h2>
</div><p>Before you consider Corbus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Corbus Pharmaceuticals 之前，您可能需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高且表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Corbus Pharmaceuticals 並不在這份名單上。</p>
</div><p>While Corbus Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Corbus 製藥目前在分析師中擁有&#34;買入&#34;評級，但頂級分析師認為以下這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Corbus 製藥控股公司（NASDAQ: CRBP）被券商給予 “買入” 的平均評級